|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh
Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M and Saad A:
Colorectal cancer epidemiology: Recent trends and impact on
outcomes. Curr Drug Targets. 22:998–1009. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang X, Yang R, Wu T, Cai X, Li G, Yu K,
Li Y, Ding R, Dong C, Li J, et al: Efficacy and safety of
neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR/MSI-H
locally advanced colorectal cancer: A single-center real-world
study. Front Immunol. 13:9134832022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou
Y, Ding R, Yang R, Tan J, Zhang L, et al: Neoadjuvant immunotherapy
for MSI-H/dMMR locally advanced colorectal cancer: New strategies
and unveiled opportunities. Front Immunol. 13:7959722022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chuang JP, Tsai HL, Chen PJ, Chang TK, Su
WC, Yeh YS, Huang CW and Wang JY: Comprehensive review of
biomarkers for the treatment of locally advanced colon cancer.
Cells. 11:37442022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vassantachart A, Marietta M, Mehta S, Lin
E and Bian SX: Racial disparities and standard treatment in locally
advanced rectal cancer: A national cancer database study. J
Gastrointest Oncol. 13:2922–2937. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Body A, Prenen H, Latham S, Lam M,
Tipping-Smith S, Raghunath A and Segelov E: The role of neoadjuvant
chemotherapy in locally advanced colon cancer. Cancer Manag Res.
13:2567–2579. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li M, Xiao Q, Venkatachalam N, Hofheinz
RD, Veldwijk MR, Herskind C, Ebert MP and Zhan T: Predicting
response to neoadjuvant chemoradiotherapy in rectal cancer: From
biomarkers to tumor models. Ther Adv Med Oncol.
14:175883592210779722022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gosavi R, Chia C, Michael M, Heriot AG,
Warrier SK and Kong JC: Neoadjuvant chemotherapy in locally
advanced colon cancer: A systematic review and meta-analysis. Int J
Colorectal Dis. 36:2063–2070. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang C, Bliggenstorfer JT, Liu J, Shearer
J, Dreher P, Bingmer K, Stein SL and Steinhagen E: Not all patients
with locally advanced rectal cancer benefit from neoadjuvant
therapy. Am Surg. 89:4327–4333. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai X, Wei B, Li L, Chen X, Yang J, Li X,
Jiang X, Lv M, Li M, Lin Y, et al: Therapeutic potential of
apatinib against colorectal cancer by inhibiting VEGFR2-mediated
angiogenesis and β-catenin signaling. Onco Targets Ther.
13:11031–11044. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen D, Zhong X, Lin L, Xie J, Lian Y and
Xu L: Comparative efficacy and adverse reactions of
apatinib-chemotherapy combinations versus chemotherapy alone for
treatment of advanced colorectal cancer: A meta-analysis of
randomized controlled trials. Am J Transl Res. 14:6703–6711.
2022.PubMed/NCBI
|
|
13
|
Dai Y, Sun L, Zhuang L, Zhang M, Zou Y,
Yuan X and Qiu H: Efficacy and safety of low-dose apatinib plus S-1
versus regorafenib and fruquintinib for refractory metastatic
colorectal cancer: A retrospective cohort study. J Gastrointest
Oncol. 13:722–731. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueno H, Hase K, Hashiguchi Y, Shimazaki H,
Tanaka M, Miyake O, Masaki T, Shimada Y, Kinugasa Y, Mori Y, et al:
Site-specific tumor grading system in colorectal cancer:
Multicenter pathologic review of the value of quantifying poorly
differentiated clusters. Am J Surg Pathol. 38:197–204. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lugli A, Kirsch R, Ajioka Y, Bosman F,
Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann
A, et al: Recommendations for reporting tumor budding in colorectal
cancer based on the international tumor budding consensus
conference (ITBCC) 2016. Mod Pathol. 30:1299–1311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chinese Society Of Clinical Oncology Csco
Diagnosis and Treatment Guidelines For Colorectal Cancer Working
Group, . Chinese society of clinical oncology (CSCO) diagnosis and
treatment guidelines for colorectal cancer 2018 (english version).
Chin J Cancer Res. 31:117–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lugano R, Ramachandran M and Dimberg A:
Tumor angiogenesis: Causes, consequences, challenges and
opportunities. Cell Mol Life Sci. 77:1745–1770. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang D, Xu F, Lai X, Li Y, Hou T, Wu L, Ma
D and Li Z: Identifying predictive biomarkers of apatinib in
third-line treatment of advanced colorectal cancer through
comprehensive genomic profiling. Anticancer Drugs. 34:431–438.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tian X, Li S and Ge G: Apatinib promotes
ferroptosis in colorectal cancer cells by targeting ELOVL6/ACSL4
signaling. Cancer Manag Res. 13:1333–1342. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y
and Lu H: Neoadjuvant immunotherapy for colorectal cancer: Right
regimens, right patients, right directions? Front Immunol.
14:11206842023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Gooyer JM, Verstegen MG, 't Lam-Boer J,
Radema SA, Verhoeven RHA, Verhoef C, Schreinemakers JMJ and de Wilt
JHW: Neoadjuvant chemotherapy for locally advanced T4 colon cancer:
A nationwide propensity-score matched cohort analysis. Dig Surg.
37:292–301. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng X, Feng H, Wu H, Jin Z, Shen X,
Kuang J, Huo Z, Chen X, Gao H, Ye F, et al: Targeting autophagy
enhances apatinib-induced apoptosis via endoplasmic reticulum
stress for human colorectal cancer. Cancer Lett. 431:105–114. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rödel C, Martus P, Papadoupolos T, Füzesi
L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R,
Sauer R and Wittekind C: Prognostic significance of tumor
regression after preoperative chemoradiotherapy for rectal cancer.
J Clin Oncol. 23:8688–8696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar R, Crouthamel MC, Rominger DH,
Gontarek RR, Tummino PJ, Levin RA and King AG: Myelosuppression and
kinase selectivity of multikinase angiogenesis inhibitors. Br J
Cancer. 101:1717–1723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pollom EL, Deng L, Pai RK, Brown JM,
Giaccia A, Loo BW Jr, Shultz DB, Le QT, Koong AC and Chang DT:
Gastrointestinal toxicities with combined antiangiogenic and
stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys.
92:568–576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spiller RC: ABC of the upper
gastrointestinal tract: Anorexia, nausea, vomiting, and pain. BMJ.
323:1354–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu
C, Shen Z, Shen K, Wang X, Liu T and Sun Y: Neoadjuvant apatinib
combined with oxaliplatin and capecitabine in patients with locally
advanced adenocarcinoma of stomach or gastroesophageal junction: A
single-arm, open-label, phase 2 trial. BMC Med. 20:1072022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liao X, Li H, Liu Z, Liao S, Li Q, Liang
C, Huang Y, Xie M, Wei J and Li Y: Clinical efficacy and safety of
apatinib in patients with advanced colorectal cancer as the
late-line treatment. Medicine (Baltimore). 97:e136352018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lugli A, Zlobec I, Berger MD, Kirsch R and
Nagtegaal ID: Tumour budding in solid cancers. Nat Rev Clin Oncol.
18:101–115. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen K, Collins G, Wang H and Toh JWT:
Pathological features and prognostication in colorectal cancer.
Curr Oncol. 28:5356–5383. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao L, Yu Q, Gao C, Xiang J, Zheng B,
Feng Y, Li R, Zhang W, Hong X, Zhan YY, et al: Studies of the
efficacy of low-dose apatinib monotherapy as third-line treatment
in patients with metastatic colorectal cancer and apatinib's novel
anticancer effect by inhibiting tumor-derived exosome secretion.
Cancers (Basel). 14:24922022. View Article : Google Scholar : PubMed/NCBI
|
